CBIO Catalyst Biosciences Inc

Catalyst Biosciences Receives US Patent for its Anti-Complement Factor 3 Portfolio of Engineered Proteases

Catalyst Biosciences Receives US Patent for its Anti-Complement Factor 3 Portfolio of Engineered Proteases
EN
14/10/2020

Underlying

CBIOCatalyst Biosciences Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Catalyst Biosciences Inc

 PRESS RELEASE
Free
CBIO Catalyst Biosci...

Catalyst Biosciences Announces Completion of Business Combination With...

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq: CBIO) (“Catalyst”) today announced completion of the business combination with GNI Group Ltd. and related entities. Catalyst received stockholder approval for all proposals necessary t...

October 30, 2023 1 EN
 PRESS RELEASE
Free
CBIO Catalyst Biosci...

Catalyst Biosciences Provides Corporate Update

Catalyst Biosciences Provides Corporate Update SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the Company’s previously announced asset purchase agreement with GNI Group Ltd (“GNI Group”) and GNI Hong Kong Limited (together “GNI”) to purchase all of the assets and intellectual property rights primarily related to GNI’s proprietary hydronidone compound outside of China (collectively, the “F351 Assets”), and the definitive agreement with GNI and oth...

February 28, 2023 1 EN
 PRESS RELEASE
Free
CBIO Catalyst Biosci...

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Catalyst Biosciences Completes First Steps in Reverse Merger Plan Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst”) and GNI Group Ltd. (2160.T) (“GNI”) today ann...

December 27, 2022 1 EN
 PRESS RELEASE
Free
CBIO Catalyst Biosci...

Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Divi...

Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Sto...

September 1, 2022 1 EN
 PRESS RELEASE
Free
CBIO Catalyst Biosci...

Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per...

Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximat...

August 25, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch